Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling.
Israel MatosMaunish BarvaliaManreet K ChehalA Gordon RobertsonIva KulicJessica A F D SilvaAbhinandan RanganathanAmy ShortYu-Hsuan HuangErin LongJohn J PriatelSalim DhanjiBrad H NelsonDanielle L KrebsKenneth W HarderPublished in: Cancer research communications (2023)
Tumor-derived GCSF leads to systemic immune population changes. GCSF blockade restores immune populations, improves immunotherapy, and reduces tumor size, paralleling human colorectal cancer data. GCSF inhibition may synergize with current immunotherapies to treat GCSF-secreting tumors.